[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pacemaker\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pacemaker":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,44,66,94,119,143,165,193,224,248,274,300,324,344,369,396,425,444],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100539105","raft---pace-ablate-100539105",false,"NCT06299514","RAFT - Pace &Ablate","Resynchronization for Ambulatory Heart Failure Trial in Patients With Chronic Atrial Fibrillation - Pharmacological Rate Control vs. Pace and Ablate With Conduction System Pacing","RAFT-P&A RCT","Inclusion Criteria:\n\n1. Patients with permanent AF\u002Fpersistent AF (in AF)\n2. Patients with NYHA Class II -IVa HF symptoms\n3. Guideline driven medical therapy (GDMT) for HF for at least 3 months:\n\n   * for those \\\u003C 75 years of age with an NT-proBNP of ≥ 600 ng\u002FL\n   * for those ≥ 75 years of age with an NT-proBNP ≥ 900 ng\u002FL, or ≥ 600 ng\u002FL if the patient has had a HF hospitalization within 1 year\n\nExclusion Criteria:\n\n1. In hospital patients needing intensive care or intravenous inotropic agent in the last 4 days\n2. Patients with a life expectancy of ≤ 1 year from non-cardiac cause or anticipating a transplant within 1 year\n3. Acute coronary syndrome \\\u003C4 weeks or coronary revascularization \\\u003C3months\n4. Unable or unwilling to provide informed consent\n5. Uncorrected primary valvular disease or prosthetic tricuspid valve\n6. Restrictive, hypertrophic, or irreversible form of cardiomyopathy\n7. Severe pulmonary diseases requiring oxygenation\n8. Patients with a known history of WHO Class I pulmonary hypertension (PH) which includes PH associated with CVD, collagen vascular disease, congenital shunts, cirrhosis and portal hypertension, HIV, hemoglobinopathies, schistosomiasis or drug-associated PH as well as those with high suspicion of irreversible pulmonary hypertension\n9. Patients enrolled in competitive clinical trials that will affect the objectives of this study\n10. Existing CRT\u002FBiVP\n11. Patients who are pregnant\n12. Guideline indication for CRT\n13. More than 20% pacing with an existing pacemaker\n14. Severe mobility limitations (ex. wheelchair bound and severe neurological conditions that limit mobility)","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","INTERVENTIONAL",[24],"NA","Atrial fibrillation (AF) is an irregular heartbeat that can cause symptoms of skipped beats, shortness of breath, stroke, or in some cases fluid in the lungs or legs. Treating AF is mostly to do with slowing the heart rate down so that the heart can get a chance to regain some energy. In some cases, slowing the heart rate is not easy to achieve as some patients find it difficult to tolerate medications and suffer side effects from these treatments. In these instances, there might be a possibility to permanently control the heart rate by implanting a pacemaker in the heart and intentionally damaging a regulatory region of the heart called the atrioventricular (AV) node. Damaging the AV node by a procedure called ablation results in the AF not being able to influence the bottom chambers (the ventricles) resulting in a slow rhythm. Therefore, if a pacemaker is implanted then the heart rate can be completely regulated by the pacemaker.\n\nA complex pacemaker that stimulates both the right and left ventricles simultaneously (BiVP) has been used for the last decade prior to AV node ablation. More recently, a technique has been designed to reduce the number of leads in the heart, reduce procedure time and have a similar effect on the heart called Conduction System Pacing (CSP). There is not enough existing evidence to show that a pace and ablate strategy is superior to optimal medical therapy. We intend to compare the efficacy of CSP with AV node ablation to optimal medical therapy for treating AF.",[27,28,29,30],"Atrial Fibrillation","Heart Failure","Pacemaker","Arrhythmia Atrial","RECRUITING","2026-06-29",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2024-04-25",{"date":39,"type":21},"2029-12-31",{"name":41,"class":42},"Habib Khan","OTHER",12,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100637987","elevated-rate-pacing-of-cardiac-amyloidosis-100637987","NCT07583823","Elevated Rate Pacing of Cardiac Amyloidosis","Inclusion Criteria:\n\n* Adults 18 and older\n* Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: \"2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee\n* Implanted Cardiac Pacemaker (+\u002F- Defibrillator)\n* Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation\n* Non-dilated left ventricle by echocardiography\n* Ability to provide written consent\n* English Speaking\n\nExclusion Criteria:\n\n* Paced QRS duration of \\>150 ms (indicator for pacing mediated dyssynchrony)\n* Dilated left ventricle",{"count":51,"type":21},10,[24],"This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.",[55,29],"Cardiac Amyloidosis","2026-05-06",{"date":58,"type":35},"2026-05-13",{"date":60,"type":35},"2025-10-10",{"date":62,"type":21},"2026-10-10",{"name":64,"class":42},"University of Minnesota",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100611123","trial-evaluating-the-benefit-of-left-bundle-branch-area-stimulation-compared-with-conventional-pacing-in-post-tavi-atrioventricular-atrioventricular-block-100611123","NCT07236489","Trial Evaluating the Benefit of Left Bundle Branch Area Stimulation Compared With Conventional Pacing in Post-TAVI Atrioventricular Atrioventricular Block","Prospective Multicenter Randomized Controlled Trial Evaluating the Benefit of Left Bundle Branch Area Stimulation Compared With Conventional Pacing in Post-TAVI Atrioventricular Atrioventricular Block","LBAP-TAVI","Inclusion Criteria:\n\n* Patients who have undergone TAVI for severe aortic valve disease within the past 3 months\n* Preserved left ventricular ejection fraction (LVEF ≥ 50%)\n* Indications for pacemaker implantation according to guidelines, including :\n* Third-degree atrioventricular (AV) block\n* Second-degree AV block Mobitz type 2 or symptomatic Mobitz type 1\n* Alternating left and right bundle branch block\n* HV interval ≥ 70 ms during electrophysiological study\n* Pre-existing right bundle branch block with worsening conduction disturbances post-TAVI\n* Prolongation of QRS and PR intervals post-procedure justifying pacemaker implantation\n* Signed informed consent\n* Patient affiliated with the national health insurance system\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction (LVEF) \\\u003C 50% before TAVI\n* Contraindication to implantation of an endocardial pacemaker (vascular access issues, sepsis)\n* Previously implanted pacemaker\n* Patients under legal guardianship, curatorship, or judicial protection\n* Participation in another interventional therapeutic clinical trial",{"count":75,"type":21},266,[24],"Transcatheter aortic valve implantation (TAVI) has rapidly expanded over the past decade as a treatment for severe aortic valve stenosis, with over 14,000 procedures performed in France in 2021. A common complication following TAVI is traumatic atrioventricular block requiring pacemaker implantation, occurring in about 10% of patients. Conventional right ventricular pacing in these cases often leads to interventricular dyssynchrony, which can impair left ventricular ejection fraction and increase the risk of hospitalization, heart failure, and mortality.\n\nCardiac resynchronization therapy via biventricular pacing is sometimes proposed as a secondary intervention but involves additional surgery. A newer pacing technique-selective left bundle branch area pacing-has been developed to provide physiological ventricular activation by stimulating conduction pathways distal to the lesion, thereby avoiding dyssynchrony. Retrospective studies suggest clinical benefits, but no prospective randomized trial has yet evaluated its efficacy compared to standard pacing.\n\nThe objective of this study is to conduct the first randomized clinical trial comparing left bundle branch area pacing versus conventional right ventricular pacing in patients requiring pacemaker implantation due to atrioventricular block after TAVI.",[79,29],"Atrioventricular Block",[29,81,82,83],"Atrioventricular block","TAVI","LBAP","2026-04-14",{"date":86,"type":35},"2026-04-15",{"date":88,"type":35},"2025-11-25",{"date":90,"type":21},"2029-11",{"name":92,"class":42},"Nantes University Hospital",7,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":65},"100536243","a-safety-and-effectiveness-monitoring-in-france-for-aveir-vr-lp-and-aveir-ar-lp-france-leadless-100536243","NCT06262295","A Safety and Effectiveness Monitoring in France for AVEIR VR LP and AVEIR AR LP (France LEADLESS)","France LEADLESS, A Safety and Effectiveness Monitoring in France for AVEIR VR LP and AVEIR AR LP","FranceLEADLESS","Inclusion Criteria:\n\n* The patient has been or will be implanted with device AVEIR VR LP and\u002For device AVEIR AR LP\n* Patient over 18 years old\n* Patient informed of the nature of the study, agrees to participate in the study\n\nExclusion Criteria:\n\n* Patient under 18 years of age\n* Patient refusing to participate in the study",{"count":103,"type":21},1000,"36 Months","OBSERVATIONAL","Although the idea of a leadless pacemaker was first proposed in the 1970s to eliminate the probes, pockets and connectors required by conventional cardiac procedures and the associated complications, the first devices were not developed until the late 2010s. Leadless pacemakers can also improve patient comfort by replacing surgery with a percutaneous procedure, eliminating the mass and scar visible at the implantation site of a conventional pacemaker, and eliminating the need for activity restrictions to prevent dislodgement after implantation of a conventional lead.\n\nThis french Registry \"France LEADLESS\" is a national registry designed to confirm the safety and efficacy of the AVEIR VR LP System in a patient population indicated for the implantation of a VVI(R) pacemaker in France and the AVEIR AR LP System in a population of patients indicated for the implantation of an AAI(R) pacemaker or both systems used in conjunction in a population of patients indicated for the implantation of a DDD(R) pacemaker. This registry will also make it possible to collect the characteristics and indications of patients under normal conditions of use.",[29],[109,29],"Leadless stimulator","2026-03-06",{"date":112,"type":35},"2026-03-09",{"date":114,"type":35},"2024-02-14",{"date":116,"type":21},"2029-09",{"name":118,"class":42},"French Cardiology Society",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100624703","increased-pacemaker-lower-rate-in-attr-cardiac-amyloidosis-100624703","NCT07413081","Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis","Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis: a Randomized, Crossover Clinical Trial (PACE-ATTR)","PACE-ATTR","Inclusion Criteria:\n\n* ATTR-CM defined as one of the following:\n* a.Positive cardiac biopsy for ATTR amyloidosis\n* b.Positive extra-cardiac biopsy for ATTR amyloidosis AND cardiac involvement demonstrated by CMR or echocardiography\n* c.Grade 2-3 uptake on DPD-scintigraphy AND negative serum free light chain and negative urine and serum immunofixation AND cardiac involvement demonstrated by CMR or echocardiography\n* Ongoing treatment with a transthyretin stabilizer or silencer OR considered not to be a candidate for these therapies with no planned initiation during the study period.\n* NYHA functional class II-III\n* Pre-existing pacemaker and either:\n* a.Atrial pacing with minimal RV pacing (\\\u003C2%), or\n* b.His bundle or left bundle branch area pacing, or\n* c.Biventricular pacing, or\n* d.Ongoing RV pacing with a high degree of RV pace (\\>80%)\n* NT-proBNP \\>600 ng\u002FL\n* Age ≥18 years\n* Ability and willingness to provide written informed consent\n* Pacing \\>80% with a programmed lower rate of 60 (AAI\u002FCSP\u002FCRT\u002FRV-pace)\n\nExclusion Criteria:\n\n* Inability to perform the 6-minute walk test.\n* Planned coronary revascularization, ablation of atrial flutter\u002Ffibrillation, or any severe (obstructive or regurgitant) valvular heart disease expected to require intervention during the trial in the investigator's opinion.\n* MI, unstable angina, coronary revascularization (percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)), ablation of atrial flutter\u002Ffibrillation, cardioversion, valve repair\u002Freplacement, hospitalization for decompensated heart failure or cardiac resynchronisation therapy within 12 weeks prior to enrollment.\n* Planned upgrade to CRT or conduction system pacing in patients with RV pacing.\n* More than moderate valvular stenosis or regurgitation\n* Inability of the patient, in the opinion of the investigator, to understand and\u002For comply with procedures and\u002For follow-up OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study\n* Presence of any other disease than heart failure with a life expectancy of \\\u003C 1year in the investigators opinion\n* Enrollment in other interventional device or drug trials during the study period, with the exception of open label extension studies\n* Listed for cardiac transplantation\n* Initiation of SGLT2-inhibitor or mineralocorticoid receptor antagonist within 4 weeks prior to enrollment\n* Initiation or change in loop diuretic therapy within 4 weeks prior to enrollment",{"count":128,"type":21},34,[24],"In cardiac amyloidosis, the heart muscle becomes thick and stiff, making it difficult to pump enough blood with each beat. The heart also often cannot increase its stroke volume, making patients with cardiac amyloidosis more dependent on having an adequate heart rate. Many develop conduction problems and need a pacemaker. In a related condition, heart failure with preserved ejection fraction, setting a higher pacemaker rate improved patients' quality of life. It is not known if the same benefits apply to amyloidosis. This study will test whether raising the pacemaker rate improves well-being and daily function in affected patients.",[55,29],"NOT_YET_RECRUITING","2026-02-09",{"date":135,"type":35},"2026-02-17",{"date":137,"type":21},"2026-02-01",{"date":139,"type":21},"2027-12-31",{"name":141,"class":42},"Region Skane",9,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":65},"100620056","remote-alert-pathway-to-optimize-care-of-cardiac-implantable-electrical-devices-the-raptor-cied-study-main-phase-100620056","NCT07352657","Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices: The RAPTOR-CIED Study (Main Phase)","RAPTOR - MAIN","Inclusion Criteria:\n\n1. Adult aged \\> 18 years\n2. Clinically stable by investigator assessment\n3. Has a newly implanted or existing wireless CIED: single, dual-chamber, biventricular, subcutaneous\u002Fextravascular, and leadless systems are all eligible, including pacemakers or implantable cardioverter-defibrillators (ICDs)\n4. CIED is from one of the 4 major CIED manufacturers in the US market (99% of implants in the US): Medtronic, Boston Scientific, Abbott, Biotronik\n5. Currently enrolled in remote monitoring as part of standard of care\n6. Primary clinical electrophysiology follow-up at the enrolling center\n7. Understands spoken and written English, Spanish, or Portuguese\n8. Has sufficient cognitive function to answer standardized questions about study rationale and procedures.\n\nExclusion Criteria:\n\n1. Presence of insertable cardiac monitor, either in isolation or in combination with any other CIED\n2. Listed for cardiac transplantation prior to enrollment (N.B. if a patient becomes listed for transplantation during the study, they may continue study participation)\n3. Participation in another study related to novel CIED technology or remote monitoring.",{"count":151,"type":21},3000,[24],"he Remote Alert Pathway to Optimize Care of Cardiac Implantable Electrical Devices (RAPTOR-CIED) Study is a pragmatic, multi-center, randomized trial with 1:1 patient-level randomization comparing the safety and effectiveness of alert-driven care versus guideline-based care for patients with wireless cardiac implantable electrical devices (CIEDs).\n\nThe study will be conducted in 2 phases: a Feasibility Phase and a Main Phase. This registration outlines the goals and design features of the Main Phase of the study.",[29,155],"Implantable Defibrillator","2026-02-04",{"date":158,"type":35},"2026-02-06",{"date":160,"type":21},"2026-12-01",{"date":162,"type":21},"2031-01-31",{"name":164,"class":42},"Beth Israel Deaconess Medical Center",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":174,"studyType":105,"phases":4,"briefSummary":175,"conditions":176,"keywords":180,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":65},"100619239","prospective-study-of-lead-associated-tricuspid-regurgitation-in-patients-undergoing-new-transvalvular-lead-insertion-100619239","NCT07342036","Prospective Study of Lead-associated Tricuspid Regurgitation in Patients Undergoing New Transvalvular Lead Insertion","LITR","Inclusion Criteria:\n\n* medically indicated for pacemaker, ICD- or CRT implantation\n* No previous diagnosis of severe tricuspid regurgitation on enrollment\n* No existing transvalvular device (must be first implantation)\n* No other diagnosed severe valvular heart disease\n* Not previous diagnosis with pre-capillary pulmonary hypertension\n* No previous diagnosis of structural disease of the right ventricle (i.e. ACM, cardiac sarcoidosis, carcinoid...)\n\nExclusion Criteria:\n\n* Patients unable to give consent\n* Under the age of 18 years\n* Relevant pre-capillary pulmonary hypertension according to decision of the heart-team (sPAP echo \\>70 mmHg)\n* Severe tricuspid valve regurgitation (Grade 3 or worse) on enrollment\n* Patients who have undergone Lead-explantation\n* Exisiting valvular heart disease requiring treatment according to the decision of the heart-team. These patients may be enrolled in the study following treatment.\n* Previous tricuspid valve surgery\n* Patients with congenital heart disease (i.e. tetralogy of fallot, Ebstein's anomaly,...)\n* Pregnant or breastfeeding women\n* Life expectancy \\\u003C 12 months",{"count":173,"type":21},200,"1 Year","The goal of this clinical trial is to record the incidence of newly developed or worsening tricuspid valve regurgitation (TR) following the implantation of a pacemaker or defibrillator with a transvenous lead. To collect this data, a transthoracic echocardiogram (TTE) with 3D imaging of the tricuspid valve (TV) will be performed before and after pacemaker implantation, with particular emphasis on assessing the tricuspid valve. Additionally, routine follow-up visits will be conducted at 6 and 12 months post-intervention, during which a TTE, ECG, NT-proBNP measurement, and pacemaker check will be performed.",[177,29,178,179],"Tricuspid Valve Regurgitation","ICD","Left Bundle Branch Area Pacing",[181,182,183],"tricuspid regurgitation","lead-related TR","lead-associated TR","2026-01-14",{"date":186,"type":35},"2026-01-16",{"date":188,"type":35},"2024-07-19",{"date":190,"type":21},"2027-01-30",{"name":192,"class":42},"Hazem Omran",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":203,"conditions":204,"keywords":208,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":65},"100611865","leadless-pacemaker-registry-outcomes-and-follow-up-from-the-university-hospital-of-st-plten-100611865","NCT07246135","Leadless Pacemaker Registry: Outcomes and Follow-up From the University Hospital of St. Pölten","Leadless Pacemaker Registry","LPR","Inclusion Criteria:\n\n* Patients undergoing implantation of a leadless pacemaker at the University Hospital of St. Pölten\n* Patients who previously received a leadless pacemaker between June 2015 and the start of the registry (retrospective inclusion).\n* Age ≥ 18 years.\n* Written informed consent provided by the patient.\n\nExclusion Criteria:\n\n* Patients who decline or are unable to provide informed consent.\n* Patients in whom a conventional transvenous pacemaker is implanted (i.e., not leadless).\n* Any condition that, in the opinion of the treating physician, precludes participation in the registry.",{"count":202,"type":21},700,"The registry for leadless pacemakers will collect and annually analyze the data of all leadless pacemaker implantations at the University Hospital St. Pölten, including demographic information, indications, procedural details, acute, medium- and long-term complications during follow-up. Due to the partially novel nature of the signals (atrial mechanical sensing markers) and the lack of long-term experience to date, data on these aspects will also be collected and analyzed.\n\nThis is a single-center, prospective and retrospective registry that includes all patients receiving a leadless pacing device, as well as all patients who received a leadless pacing device between January 2021 and the start of the registry. All patients undergoing implantation of a leadless pacemaker will be invited to participate in the registry. For patients to be included retrospectively, participation in the registry will be offered at the time of their next routine follow-up visit.\n\nThe indication for leadless pacing will be determined by the physician responsible for the patient. Enrollment in the registry will in no case alter or influence the treatment the patient receives. Data collection will take place at the time of implantation and continuously during follow-up over the entire study period. Pacemaker-related data may be obtained either in person or via remote monitoring.",[29,205,206,207],"Leadless Pacemaker","Cardiac Pacing, Artificial","Registries",[209,205,29,210,211,212,213,214],"Registry","Cardiac Pacing","Pacemaker Complication","Leadless Pacemaker Outcomes","Heart Conduction System Disease","Bradycardia","2025-11-17",{"date":217,"type":35},"2025-11-24",{"date":219,"type":35},"2015-06-18",{"date":221,"type":21},"2035-01",{"name":223,"class":42},"Karl Landsteiner University of Health Sciences",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":233,"conditions":234,"keywords":239,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":245,"leadSponsor":247,"locationsCount":4},"100608755","cardiovascular-performance-and-exercise-response-in-patients-with-persistent-or-permanent-atrial-fibrillation-and-heart-failure-pre-and-post-cardioversion-or-pace-and-ablate-100608755","NCT07205679","Cardiovascular Performance and Exercise Response in Patients With Persistent or Permanent Atrial Fibrillation and Heart Failure Pre and Post Cardioversion or Pace and Ablate","CPEX-CPA","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Persistent or Permanent Atrial Fibrillation\n3. HF - NYHA class II-IVA despite guideline-direct medical therapy\n4. Rate controlled\n5. Able to perform stress test\n6. Scheduled for clinical P\\&A OR cardioversion\n\nExclusion Criteria:\n\n1. Creatinine \\>180 μmol\u002FL or eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2\n2. Significant valvular heart disease: Moderate to severe tricuspid regurgitation, mitral regurgitation, mitral stenosis, aortic regurgitation, aortic stenosis\n3. Patients who have had a TAVI, valvular surgery, or CABG within 3 months of enrolment\n4. Right ventricular systolic pressure \\>50mmHg\n5. Existing pacemaker\n6. In sinus rhythm\n7. Predictable vasovagal syncope to pain and sight of blood",{"count":232,"type":21},40,"Heart Failure (HF) and Atrial Fibrillation (AF) are two conditions that commonly occur together. Clinical guidelines consider a resting heart rate of 100-110 beats per minute (bpm) acceptable for patients with HF and AF while 72 bpm is considered the average in healthy populations. A higher resting heart rate indicates that the heart is working harder to meet bodily demands, and though it may be considered safe for patients with HF and AF to have a heart rate of 110 bpm, the investigators believe it is having a significant negative impact on patient quality of life and their ability to exercise. The current study will test exercise ability using a treadmill test before and after either a cardioversion, where the patient's heartbeat is reset using electric shocks, or a pace and ablate method, where the patient receives a pacemaker to regulate their heart rhythm and an ablation (intentional damaging) of the node that coordinates the beats within the heart. This will allow investigators to compare how the heart responds to exercise when the patient is on rate-control and anticoagulation medication therapy (before cardioversion or pace and ablate) and after the procedures. During exercise, the investigators will do a blood test that lets investigators know how efficiently the heart is working and record any symptoms experienced. The investigators will also collect information about the patient's quality of life. Using this information, the investigators hope to better understand whether the current standard of a resting heart rate of 100-110 bpm is ideal for patient quality of life.",[235,236,29,237,238],"Atrial Fibrillation (AF)","Heart Failure - NYHA II - IV","Cardioversion","Ablation Therapy",[240],"Cardiopulmonary Exercise Testing","2025-10-01",{"date":243,"type":35},"2025-10-03",{"date":241,"type":21},{"date":246,"type":21},"2026-07",{"name":41,"class":42},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":65},"100541500","correct-mobilization-time-after-implantation-of-an-intracardiac-electronic-device-implantation-100541500","NCT06330675","Correct Mobilization Time After Implantation of an Intracardiac Electronic Device Implantation","Safety and Benefits of Mobilization at 4 Hours Compared to 24 Hours After Implantation of an Intracardiac Electronic Device: a Randomized Clinical Trial of Non-inferiority, Open and Controlled in Parallel Groups","Inclusion Criteria:\n\n* ≥ 18 years old\n* Signed informed consent form\n* New permanent pacemaker implantation (PM) or implantable cardioverter-defibrillator (ICD)\n\nExclusion Criteria:\n\n* CIED implants after recent cardiac surgery\n* Upgrade or revision of implanted device\n* CRT implantation\n* Intraoperative complications",{"count":256,"type":21},558,[24],"Bedrest is usually prescribed for patients management after cardiac electronic device implantation (CIED) in order to prevent complication. Due to the lack of guidelines available on the timing of postoperative mobilization management, the aim of the study is to evaluate the safety of early mobilization, comparing mobilization at 4-h against day-after procedure.",[29,260],"Defibrillators, Implantable",[29,262,263,264],"Implantable cardioverter-defibrillator","Early mobilization","Bed-rest","2025-08-08",{"date":267,"type":35},"2025-08-13",{"date":269,"type":35},"2023-02-01",{"date":271,"type":21},"2027-06-01",{"name":273,"class":42},"Caporali Elena",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":17,"minAge":281,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":4},"100601034","virtual-reality-in-electrophysiological-procedures-and-device-implantation-the-vr-inep-trial-100601034","NCT07105241","Virtual Reality in Electrophysiological Procedures and Device Implantation: the VR inEP Trial","VR inEP","Inclusion Criteria:\n\n* ≥16 years of age\n* Planned to undergo an invasive electrophysiological procedure (e.g., catheter ablation or electrophysiological study) or cardiac device implantation (e.g., pacemaker or implantable cardioverter defibrillator).\n* The procedure must be performed under local anesthesia.\n\nExclusion Criteria:\n\n* Patients undergoing procedures using (conscious) sedation\n* Patients who do not speak or understand Dutch\n* History of dementia\n* Severe visual impairment.","16 Years",{"count":283,"type":21},115,[24],"Each year about 37,000 patients undergo a catheter ablation to treat cardiac arrhythmias or have a cardiac device such as a pacemaker or implantable cardioverter defibrillator implanted in the Netherlands. Although the procedures positively impact health related outcomes on the long term, they are often accompanied by periprocedural pain and anxiety on a shorter term. These negative effects can be prevented or treated by pharmacological interventions (e.g. analgesics or benzodiazepines), but side effects of these drugs may compromise patient safety and extend hospital admissions. Distraction using Virtual Reality (VR) may be an attractive non-pharmacological alternative.\n\nIt is the aim of the Virtual Reality in Electrophysiological Procedures and device implantation (VR inEP) trial to study the feasibility and efficacy of VR to decrease experienced pain and anxiety in patients undergoing invasive procedures for arrhythmias and conduction disorders. The study also serves as a stepping stone towards structural implementation of VR into clinical care, by familiarizing care personnel of the cardiac catheterization rooms with the use of VR, its indications and logistics, and identifying potential barriers for structural implementation of VR.\n\nVR inEP is a single-center, open label, randomized controlled trial performed in the catheterization rooms in the Radboudumc. Adult patients undergoing an electrophysiological procedure (e.g., catheter ablation or electrophysiological study) or cardiac device implantation (e.g., pacemaker or implantable cardioverter defibrillator) performed under local anesthesia are eligible for inclusion. Patients consenting to participate are randomized in a 1:1 ratio to the VR intervention or control group, stratified for the indication for the procedure (50% electrophysiological procedures, 50% cardiac device implantations). Patients and their treatment teams are unblinded for the treatment allocation. The primary outcomes are pain perception and anxiety during the procedure as a whole, quantified using the visual analog scale (VAS) for pain and the numeric ranking scale (NRS) for anxiety, 30 minutes after the procedure ends.",[287,288,289,290,29,178],"Arrhythmia","Cardiac Implantable Electronic Device","Ablation of Arrhythmias","Electrophysiologic Study","2025-07-29",{"date":293,"type":35},"2025-08-05",{"date":295,"type":21},"2025-11-15",{"date":297,"type":21},"2026-07-31",{"name":299,"class":42},"Radboud University Medical Center",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":309,"conditions":310,"keywords":312,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":320,"leadSponsor":322,"locationsCount":4},"100600186","fluoroless-conduction-system-implant-100600186","NCT07094217","Fluoroless Conduction System Implant","Inclusion Criteria:\n\n1. Patients with a ventricular pacing indication: high grade atrioventricular block and symptomatic trifasicular, bifasicular block or left bundle branch block LBBB for cardiac resynchronisation therapy\n2. Adults willing to take part (ages 18 - 100 years old)\n3. Able to give consent.\n\nExclusion Criteria:\n\n1. Unable to give consent\n2. Children age \\\u003C 18 years and adults \\> 100 years old\n3. Pregnant patients • As per standard of care, female patients of child-bearing age will have a urine pregnancy test prior to their procedure.","100 Years",{"count":308,"type":21},75,"Conduction system pacing is a new way of stimulating the heart using pacemaker wires. Traditional pacemakers stimulate the heart muscle which causes disordered heart beats: the walls of the heart move at different times. This wears down the heart over time.\n\nConduction system pacemakers stimulate the heart's electrical system directly producing natural heart beats that are much less disordered. These pacemakers can be challenging to insert with different heart shapes, sizes and scars. This can increase procedure times and time exposed to xray as pacemakers are inserted using x-rays to guide where the lead is implanted.\n\nThis study aims to allow conduction system pacemakers to be implanted without the use of normal xray (fluoroscopy).\n\nThe investigators will create an anatomical shell of the heart using special plastic (mapping) catheters that is inserted within the heart from the groin. The investigators will use a special heart scanning (echo) catheter to see how the pacemaker wire is inserted into the heart muscle. The investigators will use MRI to confirm that the information we collect is accurate. Using this information the investigators will create a protocol to implant a lead that does not require xray, using only the mapping catheter.",[29,311],"Conduction System Pacing",[313,314,315],"fluoroless","conduction system pacing","left bundle area pacing","2025-07-28",{"date":318,"type":35},"2025-07-30",{"date":318,"type":21},{"date":321,"type":21},"2026-07-30",{"name":323,"class":42},"Imperial College London",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":65},"100586987","pacemaker-related-tricuspid-regurgitation-progression-and-long-term-outcomes-100586987","NCT06922526","Pacemaker-related Tricuspid Regurgitation Progression and Long-term Outcomes","Predictors of Tricuspid Regurgitation Progression and Adverse Outcomes in Different Pacing Modes","Inclusion Criteria:\n\n1. Adult patients\n2. Patients with an implantable electronic heart device (CIEDs)\n3. The patient underwent pacemaker implantation at Qianfoshan Hospital between 2015 and 2025\n\nExclusion Criteria:\n\n1. Patients with severe tricuspid regurgitation or those who have undergone tricuspid valve surgery or interventional treatment prior to pacemaker implantation\n2. Patients with severe valvular heart disease, congenital heart disease, or arrhythmias\n3. Patients with single-chamber pacemakers or poor images",{"count":173,"type":21},"Tricuspid regurgitation (TR) is a common complication following cardiac implantable electronic device (CIED) implantation, with severe TR being associated with increased rates of heart failure hospitalization and all-cause mortality, significantly impairing patients' quality of life. With technological advancements, physiological pacing modalities have demonstrated superior clinical efficacy and safety profiles compared to conventional pacing methods.\n\nThis study aims to evaluate predictors of adverse outcomes and TR progression in CIED recipients under different pacing modalities, thereby providing clinical guidance for high-risk patients.",[334,29],"Tricuspid Regurgitation","2025-04-26",{"date":337,"type":35},"2025-04-30",{"date":339,"type":21},"2025-04",{"date":341,"type":21},"2026-05",{"name":343,"class":42},"Haiyan Wang",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":22,"phases":354,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":65},"100377935","phase-2-optimising-pacing-for-contractility-2-100377935","NCT04201015","Optimising Pacing for Contractility 2","Mechanisms, Safety and Efficacy of Optimising Pacemaker Heart Rate for Contractility: Effects on Walk Time, Cardiac Remodelling and Quality of Life","OPT-cont 2","Inclusion Criteria:\n\n* Clinical, echocardiographic and neurohormonal evidence of heart failure\n* Cardiac pacemaker,\n* Able to perform a peak exercise test,\n* Willing and able to give informed consent.\n\nExclusion Criteria:\n\n* Angina pectoris symptoms limiting exercise tolerance,\n* Unstable heart failure symptoms (medical therapy changes in last three months), Poor image quality,\n* Calcium channel blockers (CCBs).",{"count":353,"type":21},400,[355,356],"PHASE2","PHASE3","The investigators have demonstrated that they can reliably identify an optimum heart rate range for contractility of the left ventricle in patients with chronic heart failure (CHF). They have also demonstrated in an acute cross-over and a small parallel group feasibility study that keeping the heart rate in this range (versus standard rate-response programming) in patients with CHF is associated with increased exercise time on a treadmill (around 60s or 10%). They now want to explore in a randomised, placebo-controlled 3-arm parallel group trial whether optimal programming versus standard rate-response programming versus no rate-response programming for 6 months leads to appreciable improvements in exercise time and quality of life, while having no adverse effects on left ventricular function and battery longevity and what the mechanisms of this might be.\n\n450 patients with CHF and a pacemaker will undergo the non-invasive echocardiographic assessment to establish the force frequency relationship and the optimal heart rate for contractility. They will then perform a treadmill walk test, complete quality of life questionnaires and be offered the opportunity to participate in a series of mechanistic substudies. They will then be randomised to optimal rate-response settings, standard rate response settings or no rate-response settings and followed up at 6 months at which point the tests will be repeated.",[359,29],"Heart Failure, Systolic","2024-09-24",{"date":362,"type":35},"2024-09-26",{"date":364,"type":35},"2020-06-01",{"date":366,"type":21},"2025-03-31",{"name":368,"class":42},"University of Leeds",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":378,"conditions":379,"keywords":382,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":395},"100561246","factors-affecting-selection-of-leadless-pacemaker-and-atrioventricular-synchronous-pacing-status-100561246","NCT06587672","Factors Affecting Selection of Leadless Pacemaker and Atrioventricular Synchronous Pacing Status","Factors Affecting Selection of Leadless Pacemaker in Patients With Atrioventricular Block and Atrioventricular Synchronous Pacing Status With a Micra AV: a Multicenter, Prospective, Observational Study","Inclusion Criteria:\n\n1. Patients diagnosed with atrioventricular conduction block, meeting the indications for dual-chamber leadless pacemakers as per the \"Chinese Expert Consensus on Clinical Application of Leadless Pacemakers (2022)\".\n2. Age ≥18 years.\n3. Expected lifespan ≥1 year.\n4. Consent to sign an informed consent form and cooperate in the collection of baseline data and subsequent follow-ups\n\nExclusion Criteria:\n\n1. Patients anticipated to have a high ventricular pacing proportion (\\>40%) and with left ventricular ejection fraction less than 50%.\n2. Patients with persistent atrial fibrillation and a high expected ventricular pacing proportion.\n3. Post-tricuspid valve mechanical valve replacement surgery.\n4. Patients with inferior vena cava pathway anomalies, precluding passage of the leadless pacemaker's delivery sheath.\n5. Patients with an expected lifespan of less than 1 year. 6 Patients who are pregnant, planning pregnancy, or undergoing cardiac transplantation.",{"count":377,"type":21},112,"This is a multicenter, prospective, observational study ,the aim of this study is to find factors affecting selection of double-chamber leadless pacemaker in patients with atrioventricular block and ambulatory atrioventricular synchronous pacing status over time using a leadless ventricular pacemaker.",[29,79,380,381],"Clinical Trials","Pacing",[383,384,81,385],"Leadless pacing","Atrioventricular synchrony","Atrial contraction","2024-09-04",{"date":388,"type":35},"2024-09-19",{"date":390,"type":21},"2024-09-15",{"date":392,"type":21},"2027-07-31",{"name":394,"class":42},"Xiaohan Fan",2,{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":404,"targetDuration":406,"studyType":105,"phases":4,"briefSummary":407,"conditions":408,"keywords":412,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":65},"100543464","syncope-asystole-latency-time-in-tilt-table-test-the-salt-tilt-study-100543464","NCT06356207","Syncope-Asystole Latency Time in Tilt Table Test: The SALT-TILT Study","NeuroArrhythmias Area Registry of AIAC (NAARA) Syncope-Asystole Latency Time in Tilt Table Test (SALT-TILT) Study","SALT-TILT","Inclusion Criteria:\n\n* Patients eligible for invasive treatment according to the ESC Guidelines for pacing 2021\n* Written informed consent\n\nExclusion Criteria:\n\n* Other condition which explains syncope cause other than reflex syncope\n* Structural heart disease (valvular, ischaemic, cardiomyopathies)\n* Pregnancy\n* Patient denial to be recorded on video during tilt table test",{"count":405,"type":21},64,"2 Years","Syncope is a common presenting condition. Pacemaker implantation can significantly reduce syncope recurrences in reflex syncope. However, despite careful selection, a substantial proportion of patients treated with pacemakers suffer recurrences of syncope. It is thought that a pronounced vasodepressor component may hinder the efficacy of pacing in patients, preventing adequate cerebral perfusion during the reflex, thus relativizing the anti-bradycardia function of the pacemaker to prevent syncope. It is hypothesised that the time elapsed from the actual loss of consciousness to the asystole recorded on the ECG during Tilt Table Test may be predictive in terms of response to pacemaker therapy, so this parameter becomes the subject of the present study.",[409,29,410,411],"Syncope","Asystole","Neurally Mediated Syncope",[409,29,413,410,414,415],"Tilt Table Test","SALT","Syncope-Asystole Latency Time","2024-04-10",{"date":418,"type":35},"2024-04-11",{"date":420,"type":35},"2024-03-20",{"date":422,"type":21},"2027-03",{"name":424,"class":42},"Azienda Ospedaliera di Bolzano",{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":306,"enrollmentInfo":431,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":65},"100434009","clinical-study-of-impact-of-different-pacing-site-in-patients-100434009","NCT04931550","Clinical Study of Impact of Different Pacing Site in Patients","Inclusion Criteria:\n\n* Patients who received pacemaker implantation in the Second Hospital of Zhejiang Medical University by Pan Xiaohong and other surgeons.\n* Patients who have the ability to understand the test and can cooperate with investigators.\n\nExclusion Criteria:\n\n* Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors.",{"count":20,"type":21},"At present, cardiac pacing has been widely used in the treatment of bradyarrhythmias and heart failure, which can effectively improve the survival rate of patients. With the rapid development of technology, different sites can be chosen to pace, such as right atrial appendage, the atrial septum and the right atrial wall in the atrium, His bundle, left bundle branch area, right ventricular apex, outflow tract, and left ventricular pacing via coronary vein in the ventricle. There are few studies comparing the long-term efficacy and safety of different pacing sites in daily practice. This study aims to observe the efficacy and safety of cardiac pacing at different sites in short and long term, and to compare the advantages and disadvantages of pacing at different sites.",[434,28,29],"Bradyarrhythmias","2023-01-29",{"date":437,"type":35},"2023-01-31",{"date":439,"type":35},"2020-08-01",{"date":441,"type":21},"2026-12",{"name":443,"class":42},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":445,"slug":446,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":17,"minAge":451,"maxAge":4,"enrollmentInfo":452,"targetDuration":454,"studyType":105,"phases":4,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":65},"100444798","monaldi-hospital-rhythm-registry-100444798","NCT05072119","Monaldi Hospital Rhythm Registry","Registry of Patients Underwent Cardiac Implanted Electronic Device Implantation at Monaldi Hospital","Inclusion Criteria:\n\n* All consecutive patients underwent PM\u002FICD\u002FILR implantation\n* Patient is willing and able to sign an authorization to use and disclose health information or an Informed Consent\n* Patient must be able to attend all required follow-up visits at the study center for at least 12 months\n\nExclusion Criteria:\n\n* No informed consent\n* Patient is participating in another clinical study that may have an impact on the study endpoint\n\nExclusion Criteria:\n\n* No informed consent","14 Years",{"count":453,"type":21},5000,"20 Years","The study is a prospective registry. Consecutive patients with indications of implant \u002F replacement or upgrade of pacemaker (PM), implantable cardioverter defibrillator (ICD), Implanted loop recorder (ILR) will be enrolled.\n\nThe primary objective of the study is to describe the clinical events during a long-term follow-up of non-selected population of patients implanted with an PM, ICD or ILR.",[29,178,457],"Implanted Loop Recorder","2021-10-08",{"date":460,"type":35},"2021-10-15",{"date":462,"type":35},"2015-01-07",{"date":464,"type":21},"2050-01",{"name":466,"class":42},"University of Campania Luigi Vanvitelli"]